Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Comcast Corporation (CMCSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Comcast Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Comcast Corporation trades at $23.25 (market cap $82.84B). The key difference: Comcast Corporation is far larger — about 10.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Comcast Corporation pays a 5.69% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | CMCSA | |
|---|---|---|
Market Cap | $8.04B | $82.84B |
Sector | Health | Media |
52-Week High | $339.75 | $33.81 |
52-Week Low | $241.71 | $22.32 |
Enterprise Value | $7.85B | $167.98B |
Dividend Yield | — | 5.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Comcast (CMCSA) trades at $23.97, up 1.7% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 16.16% net margin and attractive valuation metrics including P/E of 4.7 and P/B of 0.97. Recent quarterly earnings consistently beat expectations, while strategic moves include the NBCUniversal spin-off and Sky's acquisition of ITV's media unit for $2.14 billion.
The stock presents compelling value with significant upside to the $29.94 consensus target. However, investors face risks from Starlink competition and integration challenges from recent acquisitions. Wall Street maintains strong buy sentiment with 58% analyst support, but execution risks and sector disruption threats warrant careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
